Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma
Previous
Previous
Axxess Names Home Care Expert Patricia Drea to Senior Leadership Team
Next
Next